• Parvovirus B19-viremia. Clinical and laboratory presentation
en To content Full text of article

Parvovirus B19-viremia. Clinical and laboratory presentation

Modern Pediatrics.Ukraine.2020.3(107):77-86; doi 10.15574/SP.2020.107.77
Dorosh O. I.1,2,3, Petronchak O. A.4, Guley R. V.4, Seleznyov A. A.5, Mykh A. N.1,6, Melko I. P.1,7, Skaletska N. М.2, Seredych L. P.1,8
1Сommunal noncommercial enterprise of Lviv regional council «Western Ukrainian Specialized Children's Medical Centre», Lviv, Ukraine
2Danylo Halytskyy Lviv National Medical University, Lviv, Ukraine
3«Doctor Smart» Hematology Clinic, Lviv, Ukraine
4Private limited company «Western Histology Laboratory», Lviv, Ukraine|
5Pathomorphological Laboratory «CSD Health Care», Kyiv, Ukraine
6Medical Center of St. Paraskeva, Lviv, Ukraine
7Center for Medical Innovations NOVO, Lviv, Ukraine
8Private Medical Center «MiniPoliklinika», Lviv, Ukraine

For citation: Dorosh OI, Petronchak OA, Guley RV, Seleznyov AA et al. (2020). Parvovirus B19-viremia. Clinical and laboratory presentation. Modern Pediatrics. Ukraine. 3(107): 77-86; doi 10.15574/SP.2020.107.77
Article received: Dec 18, 2019. Accepted for publication: Mar 29, 2020.

Parvovirus B19 (PVB19), (formerly erythrovirus B19) is the etiological agent of the so-called «Fifth disease», which is mainly found in childhood and adoles-cence, but is also associated with polymorphic clinical presentation, aplastic crises, hemolytic anemia, thrombocytopenia etc., and in pregnant women — unauthorized abortions.
Clinical case. Reported a case of PVB19 viremia, which in a 2-year-old patient was the cause of systemic damage. Attention is focused on the long-term differential diagnosis of exanthema in combination with hepatosplenomegaly, polyserositis and leukopenia with neutropenia, anemia and thrombocytopenia of infectious and non-infectious origin, including excluded the neoplastic process, collagenosis. To verify the diagnosis, numerous microbiological tests, aspiration and trepanation bone marrow (BM) biopsy were performed, puncture of pleural fluid, skin biopsy, imaging methods were used: ultrasound (ultrasound), chest Х-ray, computed tomography. In ВM, cytological and histological studies revealed giant erythroid cell elements in the pronormoblast stage with pronounced intranuclear inclusions with chromatin pressed to the periphery of the nucleus, which led to the suspicion of PVB19 infection, which was confirmed using the polymerase chain reaction method. Recovery of the child occurred after the use of methylprednisolone at a dose of 2.7 mg/kg for 28 days with a gradual withdrawal of the medication.
Conclusions. In our opinion, this topic is relevant in the practice of doctors of various specialties, since the timeliness, adequacy and result of treatment depend on the correct verification of the clinical diagnosis.
The research was carried out in accordance with the principles of the Helsinki Declaration. The study protocol was approved by the Local Ethics Committee of all participating institution. The informed consent of the child's parents was obtained for the research.
No conflict of interest was declared by the authors.
Key words: parvovirus B19, hemorrhagic maculopapular dermatitis, polyserositis, hepatosplenomegaly, leukopenia, neutropenia, thrombocytopenia, anemia, children.


1. Abarca K, Cohen BJ, Vial PA. (2002). Seroprevalence of parvovirus B19 in urban Chilean children and young adults, 1990 and 1996. Epidemiol Infect. 128: 59–62. https://doi.org/10.1017/S0950268801006203; PMid:11895091 PMCid:PMC2869795

2. Aktepe OC, Yetgin S, Olcay L, Ozbek N. (2004). Human parvovirus B19 associated with idiopathic thrombocytopenic purpura. Pediatr Hematol Oncol. 21(5): 421–426. https://doi.org/10.1080/08880010490457141; PMid:15205085

3. Andrade RJ, Tulkens PM. (2011). Hepatic safety of antibiotics used in primary care. J Antimicrob Chemother. 66(7): 1431–1446. https://doi.org/10.1093/jac/dkr159; PMid:21586591 PMCid:PMC3112029

4. Aslanidis S, Pyrpasopoulou A, Kontotasios K et al. (2008). Parvovirus B19 infection and systemic lupus erythematosus: activation of an aberrant pathway? Eur J Intern Med. 19: 314–318. https://doi.org/10.1016/j.ejim.2007.09.013; PMid:18549931

5. Bhattacharyya J, Kumar R, Tyagi S et al. (2005). Human parvovirus B19-induced acquired pure amegakaryocytic thrombocytopenia. Br J Haematol. 128(1): 128–129. https://doi.org/10.1111/j.1365-2141.2004.05252.x; PMid:15606559

6. Bousvaros A, Sundel R, Thorne GM, McIntosh K et al. (1998). Parvovirus B19-associated interstitial lung disease, hepatitis, and myositis. Pediatr Pulmonol. 26: 365–369. https://doi.org/10.1002/(SICI)1099-0496(199811)26:5<365::AID-PPUL11>3.0.CO;2-4

7. Broliden K, Tolfvenstam T, Norbeck O. (2006). Clinical aspects of parvovirus B19 infection. J Intern Med. 260(4): 285–304. https://doi.org/10.1111/j.1365-2796.2006.01697.x; PMid:16961667

8. Bultmann BD, Klingel K, Sotlar K et al. (2003). Parvovirus B19: a pathogen responsible for more than hematologic disorders. Virchows Arch. 442(1): 8–17. https://doi.org/10.1007/s00428-002-0732-8; PMid:12536309

9. Castagna L, Furst S, El Cheikh J et al. (2011). Parvovirus B19 as an etiological agent of acute pleuro-pericarditis. Bone Marrow Transplant. 46(2): 317–318. https://doi.org/10.1038/bmt.2010.103; PMid:20421866

10. Claver Belver N, Sanfeliu Sala I, Merino Asensio MJ et al. (2019). Erythrovirus B19 infections. Six years of follow0up in adults and children. An Pediatr (Barc). 90(5): 280–284. https://doi.org/10.1016/j.anpede.2018.05.008

11. Crayne CB, Albeituni S, Nichols KE, Cron RQ. (2019). The Immunology of Macrophage Activation Syndrome. Front Immunol. 10: 119. https://doi.org/10.3389/fimmu.2019.00119; PMid:30774631 PMCid:PMC6367262

12. Diaz F, Collazos J. (2000). Hepatic dysfunction due to parvovirus B19 infection. J Infect Chemother. 6: 63–64. https://doi.org/10.1007/s101560050052; PMid:11810534

13. Drago F, Ciccarese G, Broccolo F, Javor S, Parodi A. (2015). Atypical exanthems associated with Parvovirus B19 (B19V) infection in children and adults. J Med Virol. 87(11): 1981–1984. https://doi.org/10.1002/jmv.24246; PMid:25965702

14. Ferrari B, Diaz MS, Lopez M, Larralde M. (2018). Unusual skin manifestations associated with parvovirus B19 primary infection in children. Pediatr Dermatol. 35(6): e341-e344. https://doi.org/10.1111/pde.13623; PMid:30230024

15. Fortna RR, Toporcer M, Elder DE, Junkins-Hopkins JM. (2010). A case of sweet syndrome with spleen and lymph node involvement preceded by parvovirus B19 infection, and a review of the literature on extracutaneous sweet syndrome. Am J Dermatopathol. 32(6): 621–627. https://doi.org/10.1097/DAD.0b013e3181ce5933; PMid:20534986

16. Frotscher B, Salignac S, Morlon L, Bonmati C et al. (2009). Neutropenia and/or thrombocytopenia due to acute parvovirus B19 infection. Ann Biol Clin (Paris). 67(3): 343–348. https://doi.org/10.1684/abc.2009.0324; PMid:19411238

17. Gabriel SE, Espy M, Erdman DD, Bjornsson J et al. (1999). The role of parvovirus B19 in the pathogenesis of giant cell arteritis: A preliminary evaluation. Arthritis Rheum. 42(6): 1255–1258. https://doi.org/10.1002/1529-0131(199906)42:6<1255::AID-ANR23>3.0.CO;2-P

18. Gaggero A, Rivera J, Calquin E, Larranaga C E et al. (2007). Seroprevalencia de anticuerpos IgG contra parvovirus B19 en donantes de sangre de hospitales en Santiago, Chile. Rev Med Chile. 135(4): 443–448. https://doi.org/10.4067/S0034-98872007000400005; PMid:17554452

19. Galel SA, Malone JM, Vivele MK. (2004). Transfusion Medicine. In Greer JP, Rodgers GM, Foerster J, Paraskevas F, Lukens JN, Glader B. Wintrobe’s clinical hematology. 11th ed. Philadelphia: Lippincott Williams & Wilkins: 869–870.

20. Gallinella G. (2018). The clinical use of parvovirus B19 assays: recent advances. Expert Rev Mol Diagn. 18(9): 821–832. https://doi.org/10.1080/14737159.2018.1503537; PMid:30028234

21. Garcia-Tapia AM, Martinez-Rodriguez A, Fernandez-Gutierrez C et al. (1993). Bullous erythema multiforme caused by human parvovirus B19. Enferm Infecc Microbiol Clin. 11(10): 575–576.

22. Garcia-Tapia AM, Lozano Dominguez MC, Fernandez Gutiirrez del Alamo C. (2005). Diagnostico microbiologico de la infeccion por Erythovirus B19. Documento Control Calidad SEIMC. Consultado 15 de Jul 2016. https://doi.org/10.1157/13094275; PMid:17125665

23. Gelmetti C, Caputo R. (2001). Asymmetric periflexural exanthem of childhood: who are you? J Eur Acad Dermatol Venereol. 15(4): 293–294. https://doi.org/10.1046/j.1468-3083.2001.00298.x; PMid:11730033

24. Guimera-Martin-Neda F, Fagundo E, Rodriguez F, Cabrera R et al. (2006). Asymmetric periflexural exanthem of childhood: Report of two cases with parvovirus B19. J Eur Acad Dermatology Venereol. 20(4): 461—462. https://doi.org/10.1111/j.1468-3083.2006.01443.x; PMid:16643150

25. Hartel C, Herz A, Vieth S et al. (2007). Renal complications associated with human parvovirus B19 infection in early childhood. Klin Padiatr. 219(2): 74—75. https://doi.org/10.1055/s-2007-970071; PMid:17405071

26. Hu HY, Wei SY, Huang WH, Pan CH. (2019). Fatal parvovirus B19 infections: a report of two autopsy cases. Int J Legal Med. 133(2): 553—560. https://doi.org/10.1007/s00414-018-1921-6; PMid:30173301 PMCid:PMC7088123

27. Islek A, Keskin H, Agin M et al. (2019). Parvovirus B19 Infection as a Rare Cause of Fulminant Liver Failure: A Case Report. Transplant Proc. 51(4): 1169—1171. https://doi.org/10.1016/j.transproceed.2019.01.084; PMid:31101193

28. Istomin V, Shin H, Park S, Lee GW et al. (2019). Parvovirus B19 infection presenting with neutropenia and thrombocytopenia: Three case reports. Medicine (Baltimore). 98(35): e16993. https://doi.org/10.1097/MD.0000000000016993; PMid:31464949 PMCid:PMC6736112

29. Istomin V, Sade E, Grossman Z, Rudich H et al. (2019). Agranulocytosis associated with parvovirus B19 infection in otherwise healthy patient. Eur J Intern Med. 15(8): 531—533. https://doi.org/10.1016/j.ejim.2004.11.002; PMid:15668091

30. Izquierdo-Blasco J, Salcedo Allende MT, Codina Grau MG et al. (2020). Parvovirus B19 Myocarditis: Looking Beyond the Heart. Pediatr Dev Pathol. 23(2): 158—162. https://doi.org/10.1177/1093526619865641; PMid:31335286

31. Kerr JR. (2016). The role of parvovirus B19 in the pathogenesis of autoimmunity and autoimmune disease. J Clin Pathol. 69(4): 279—291. https://doi.org/10.1136/jclinpath-2015-203455; PMid:26644521

32. Klepfish A, Rachmilevitch E, Schattner A. (2006). Parvovirus B19 reactivation presenting as neutropenia after rituximab treatment. Eur J Intern Med. 17: 505—507. https://doi.org/10.1016/j.ejim.2006.05.002; PMid:17098597

33. Koliou M, Karaoli E, Soteriades ES, Pavlides S et al. (2014). Acute hepatitis and myositis associated with Erythema infectiosum by Parvovirus B19 in an adolescent. BMC Pediatr. 14:6. https://doi.org/10.1186/1471-2431-14-6; PMid:24410941 PMCid:PMC3937157

34. Kouklakis G, Mpoumponaris A, Zezos P, Moschos J et al. (2007). Cholestatic hepatitis with severe systemic reactions induced by trimethoprim-sulfamethoxazole. Ann Hepatol. 6(1): 63—65. https://doi.org/10.1016/S1665-2681(19)31956-8

35. Kucers A, Crowe S, Grayson ML, Hoy J. (1997). The Use of Antibiotics. A Clinical Review of Antibacterial, Antifungal and Antiviral Drugs. 5 ed. Oxford, UK: Butterworth-Heinemann. 1992.

36. Lazzerini PE, Cusi MG, Selvi E, Capecchi M et al. (2018). Non-HCV-related cryoglobulinemic vasculitis and parvovirus-B19 infection. Jt Bone Spine. 85(1): 129–130. https://doi.org/10.1016/j.jbspin.2016.12.013; PMid:28062379

37. Le Scanff J, Vighetto A, Mekki Y, Nguyen AM et al. (2010). Acute ophthalmoparesis associated with human parvovirus B19 infection. Eur J Ophthalmol. 20(4): 802–804. https://doi.org/10.1177/112067211002000428; PMid:20155703

38. Lilleberg HS, Eide IA, Geitung JT, Svensson MHS. (2018). Acute glomerulonephritis triggered by parvovirus B19. Tidsskr Nor Laegeforen. 138(17).

39. Lobkowicz F, Ring J, Schwarz TF, Roggendorf M. (1989). Erythema multiforme in a patient with acute human parvovirus B19 infection. J Am Acad Dermatol. 20(5 Pt1): 849–580. https://doi.org/10.1016/S0190-9622(89)80120-3

40. Mace G, Sauvan M, Castaigne V, Moutard ML et al. (2014). Clinical presentation and outcome of 20 fetuses with parvovirus B19 infection complicated by severe anemia and/or fetal hydrops. Prenat Diagn. 34(11): 1023–1030. https://doi.org/10.1002/pd.4413; PMid:24851784

41. Macri A, Crane JS. (2020). Parvoviruses. StatPearls. Treasure Island (FL): Stat Pearls Publishing; 2020–.2020 Mar 4.

42. Malbora B, Saritas S, Ataseven E, Belen B et al. (2017). Pure Red Cell Aplasia Due to Parvovirus B19: Erythropoietin-Resistant Anemia in a Pediatric Kidney Recipient. Exp Clin Transplant. 15(3): 369–371.

43. Meyer P, Jeziorski E, Bott-Gilton L, Foulongne V et al. (2011). Childhood parvovirus B19 encephalitis. Arch Pediatr. 18(12): 1315–1319. https://doi.org/10.1016/j.arcped.2011.08.013; PMid:21963073

44. Miron D, Luder A, Horovitz Y, Izkovitz A et al. (2006). Acute human parvovirus B019 infection in hospitalized children: A serologic and molecular survey. Pediatr Infect Dis J. 25(10): 898–901. https://doi.org/10.1097/01.inf.0000237865.01251.d2; PMid:17006284

45. Neely G, Cabrera R, Hojman L. (2018). Parvovirus B19: A DNA virus associated with multiple cutaneous manifestations. Rev Chilena Infectol. 35(5): 518—530. https://doi.org/10.4067/s0716-10182018000500518; PMid:30724999

46. Nigro G, Zerbini M, Krzysztofiak A, Gentilomi G et al. (1994). Active or recent parvovirus B19 infection in children with Kawasaki disease. Lancet (London, England). 343(8908): 1260—1261. https://doi.org/10.1016/S0140-6736(94)92154-7

47. Oliver ND, Millar A, Pendleton A. (2012). A case report on parvovirus b19 associated myositis. Case Rep Rheumatol. 2012: 250537. https://doi.org/10.1155/2012/250537; PMid:23304613 PMCid:PMC3523589

48. Olivier-Gougenheim L, Dijoud F, Traverse-Glehen A, Benezech S et al. (2019). Aggressive large B-cell lymphoma triggered by a parvovirus B19 infection in a previously healthy child. Hematol Oncol. 37(4): 483—486. https://doi.org/10.1002/hon.2665 ;PMid:31408541

49. Ozbek OY, Onay OS, Kinik ST, Ozbek N. (2007). Laryngitis and neutropenia from parvovirus-B19. Indian J Pediatr. 74(10): 950—952. https://doi.org/10.1007/s12098-007-0176-x; PMid:17978457

50. Poole BD, Karetnyi YV, Naides SJ. (2004). Parvovirus B19-induced apoptosis of hepatocytes. J Virol. 78: 7775—7783. https://doi.org/10.1128/JVI.78.14.7775-7783.2004; PMid:15220451 PMCid:PMC434113

51. Qiu J, Soderlund-Venermo M, Young NS. (2017). Human parvoviruses. Clin Microbiol Rev. 30(1): 43—113. https://doi.org/10.1128/CMR.00040-16; PMid:27806994 PMCid:PMC5217800

52. Ravelli A, Davi S, Minoia F, Martini A, Cron RQ. (2015). Macrophage Activation Syndrome. Hematol Oncol Clin North Am. 29(5): 927—941. https://doi.org/10.1016/j.hoc.2015.06.010; PMid:26461152

53. Rogo LD, Mokhtari-Azad T, Kabir MH, Rezaei F. (2014). Human parvovirus B19: a review. Acta Virol. 58(3): 199—213. https://doi.org/10.4149/av_2014_03_199; PMid:25283854

54. Saeki T, Shibuya M, Sawada H et al. (2001). Human parvovirus B19 infection mimicking systemic lupus erythematosus. Mod Rheumatol. 11: 308—313. https://doi.org/10.3109/s10165-001-8061-3; PMid:24383775

55. Sanz-Sanchez T, Dauden E, Moreno de Vega MJ, Garcia-Diez A. (2006). Parvovirus B19 primary infection with vasculitis: DNA identification in cutaneous lesions and sera. J Eur Acad Dermatol Venereol. 20(5): 618—620. https://doi.org/10.1111/j.1468-3083.2006.01502.x; PMid:16684303

56. Seishima M, Shibuya Y, Watanabe K, Kato G. (2010). Pericarditis and pleuritis associated with human parvovirus B19infection in a systemic lupus erythematosus patient. Mod Rheumatol. 20(6): 617—620. https://doi.org/10.3109/s10165-010-0330-6; PMid:20607339

57. Seo JY, Kim HJ, Kim SH. (2011). Neutropenia in parvovirus B19-associated pure red cell aplasia. Ann Hematol. 90: 975. https://doi.org/10.1007/s00277-010-1108-9; PMid:21052671

58. Servey JT, Reamy BV, Hodge J. (2007). Clinical presentations of parvovirus B19 infection. Am Fam Physician. 75(3): 373—376.

59. Sharada Raju R, Nalini Vinayak K, Madhusudan Bapat V et al. (2014). Acute human parvovirus b19 infection: cytologic diagnosis. Indian J Hematol Blood Transfus. 30(1): 133—134. https://doi.org/10.1007/s12288-013-0287-7; PMid:25332559 PMCid:PMC4192177

60. Shin H, Park S, Lee GW et al. (2019). Parvovirus B19 infection presenting with neutropenia and thrombocytopenia: Three case reports. Medicine (Baltimore). 98(35): e16993. https://doi.org/10.1097/MD.0000000000016993; PMid:31464949 PMCid:PMC6736112

61. Sokumbi O, Wetter DA. (2012). Clinical features, diagnosis, and treatment of erythema multiforme: a review for the practicing dermatologist. Int J Dermatol. 51(8): 889—902. https://doi.org/10.1111/j.1365-4632.2011.05348.x; PMid:22788803

62. Spartalis M, Tzatzaki E, Spartalis E, Damaskos C et al. (2017). Parvovirus B19 Myocarditis of Fulminant Evolution.Cardiol Res. 8(4): 172—175. https://doi.org/10.14740/cr580w; PMid:28868104 PMCid:PMC5574291

63. Tizeba YA, Mirambo MM, Kayange N, Mhada T et al. (2018). Parvovirus B19 Is Associated with a Significant Decrease in Hemoglobin Level among Children <5 Years of Age with Anemia in Northwestern Tanzania. J Trop Pediatr. 64(6): 479—487. https://doi.org/10.1093/tropej/fmx099; PMid:29244176

64. Uchida T, Oda T, Watanabe A, Yamamoto K et al. (2014). Transition from endocapillary proliferative glomerulonephritis to membranoproliferative glomerulonephritis in a patient with a prolonged human parvovirus B19 infection. Clin Nephrol. 82(1): 62—67. https://doi.org/10.5414/CN107822

65. Valentin MN, Cohen PJ. (2013). Pediatric parvovirus B19: spectrum of clinical manifestations. Cutis. 92(4): 179—184.

66. Veraldi S, Mancuso R, Rizzitelli G et al. (1999). Henoch-Schonlein syndrome associated with human parvovirus B19 primary infection. Eur J Dermatol. 9(3): 232—233.

67. Yermalovich MA, Hubschen JM, Semeiko GV et al. (2012). Human parvovirus B19 surveillance in patients with rash and fever from Belarus. J Med Virol. 84(6): 973—978. https://doi.org/10.1002/jmv.23294; PMid:22499021

68. Young NS, Brown KE. (2004). Parvovirus B19. N Engl J Med.350: 586—597. https://doi.org/10.1056/NEJMra030840; PMid:14762186

69. Young NS. (2006). Hematologic manifestations and diagnosis of parvovirus B19 infections. Clin Adv Hematol Oncol. 4(12): 908—910.

70. Zaki Mel S, Hassan SA, Seleim T, Lateef RA. (2006). Parvovirus B19 infection in children with a variety of hematological disorders. Hematology. 11(4): 261—266. https://doi.org/10.1080/10245330600841089; PMid:17178665

71. Zeckanovic A, Perovnik M, Jazbec J, Kavcic M. (2018). Spectrum of Parvovirus B19 Infection Presentations in Children with Underlying Hematooncologic Disorders: A Case Series. Klin Padiatr. 230(6): 330—332. https://doi.org/10.1055/a-0594-9362; PMid:29660757

72. Zikidou P, Grapsa A, Bezirgiannidou Z, Chatzimichael A, Mantadakis E. (2018). Mediterr J Hematol Infect Dis. 10(1): e2018018. https://doi.org/10.4084/mjhid.2018.018; PMid:29531655 PMCid:PMC5841940